Aliases & Classifications for Purpura

MalaCards integrated aliases for Purpura:

Name: Purpura 12 74 54 43 15 71
Purpuric Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3326
MeSH 43 D011693
NCIt 49 C78787
SNOMED-CT 67 12393003
ICD10 32 D69.2
UMLS 71 C0034150

Summaries for Purpura

MalaCards based summary : Purpura, also known as purpuric disorder, is related to henoch-schoenlein purpura and purpura fulminans, and has symptoms including pruritus, hemoptysis and flushing. An important gene associated with Purpura is ADAMTS13 (ADAM Metallopeptidase With Thrombospondin Type 1 Motif 13), and among its related pathways/superpathways are TGF-Beta Pathway and Akt Signaling. The drugs Lansoprazole and Dexlansoprazole have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and t cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 74 Purpura (/'p??rpj??r?/) is a condition of red or purple discolored spots on the skin that do not blanch... more...

Related Diseases for Purpura

Diseases related to Purpura via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1658)
# Related Disease Score Top Affiliating Genes
1 henoch-schoenlein purpura 34.7 MEFV CRP CD79A CD40LG
2 purpura fulminans 34.2 SERPINC1 PROC F3 F2
3 thrombotic thrombocytopenic purpura 33.9 VWF THBD SERPINC1 ITGB3 F3 CD40LG
4 thrombocytopenic purpura, autoimmune 33.8 THPO MPL ITGB3 ITGA2B CD40LG ADAMTS13
5 thrombotic microangiopathy 33.3 VWF ADAMTS13
6 hypersensitivity vasculitis 32.9 MEFV CRP CD40LG ACE
7 protein c deficiency 32.8 THBD SERPINC1 PROC F2
8 evans' syndrome 32.7 THPO MPL CD40LG ADAMTS13
9 thrombocytopenia due to platelet alloimmunization 32.6 TNFSF13B THPO MPL ITGB3 ITGA2B IL10
10 fetal and neonatal alloimmune thrombocytopenia 32.5 ITGB3 ITGA2B
11 adult-onset still's disease 32.4 TNF MEFV IL6 CRP
12 protein s deficiency 32.3 THBD SERPINC1 PROC F3 F2
13 cryoglobulinemia 32.2 TNFSF13B TNF IL6 IL10 CD79A CD40LG
14 proteasome-associated autoinflammatory syndrome 1 32.2 TNF MEFV IL6 IL10 CRP
15 heparin-induced thrombocytopenia 31.5 SERPINC1 F3 CD40LG
16 iga glomerulonephritis 31.5 CD79A CD40LG ACE
17 acquired thrombocytopenia 31.4 THPO MPL ITGB3
18 hemolytic anemia 31.4 VWF THBD F3 CD40LG ADAMTS13
19 factor viii deficiency 31.3 VWF F3 F2
20 von willebrand's disease 31.3 VWF ITGB3 F3 F2 ADAMTS13
21 acquired von willebrand syndrome 31.3 VWF F3 ADAMTS13
22 gray platelet syndrome 31.2 VWF ITGA2B CD40LG
23 rubella 31.1 TNF IL6 IL10 CD40LG
24 catastrophic antiphospholipid syndrome 31.1 PROC F3 CD40LG ADAMTS13
25 meningococcemia 31.1 THBD SERPINC1 PROC
26 intussusception 31.1 IL6 CRP CD40LG
27 thyroiditis 31.0 TNF IL6 IL10
28 factor xii deficiency 31.0 VWF SERPINC1 F3
29 factor vii deficiency 31.0 SERPINC1 F3 F2
30 factor x deficiency 31.0 VWF F3 F2
31 mumps 31.0 TNF IL6 IL10 CD40LG
32 al amyloidosis 30.9 VWF ADAMTS13
33 hemolytic-uremic syndrome 30.9 VWF THBD F3 F2 CD40LG ADAMTS13
34 factor xiii deficiency 30.9 VWF SERPINC1 F3 F2
35 bernard-soulier syndrome 30.9 VWF THPO ITGB3 ITGA2B F2
36 hemophilia b 30.8 VWF SERPINC1 F3 F2
37 mesangial proliferative glomerulonephritis 30.8 IL6 CD79A CD40LG
38 ileitis 30.8 TNF IL6 IL10
39 guillain-barre syndrome 30.8 TNF CD79A CD40LG
40 diarrhea 30.8 TNF IL6 IL10 CD40LG
41 afibrinogenemia, congenital 30.8 VWF SERPINC1 F3 F2
42 macroglobulinemia 30.7 TNFSF13B IL6 CD40LG
43 chickenpox 30.7 TNF IL6 IL10 CRP CD40LG
44 polyarteritis nodosa 30.7 MEFV IL6 CRP
45 hemolytic uremic syndrome, atypical 1 30.7 VWF THBD F3 ADAMTS13
46 qualitative platelet defect 30.7 VWF ITGA2B F3 F2
47 cryofibrinogenemia 30.7 CD79A CD40LG
48 glanzmann thrombasthenia 30.7 VWF ITGB3 ITGA2B F3 F2
49 malignant hypertension 30.7 VWF THBD ADAMTS13 ACE
50 acute pancreatitis 30.7 TNF IL6 IL10 CRP

Graphical network of the top 20 diseases related to Purpura:



Diseases related to Purpura

Symptoms & Phenotypes for Purpura

UMLS symptoms related to Purpura:


pruritus, hemoptysis, flushing, icterus, petechiae of skin, skin manifestations, integumentary system signs and symptoms

MGI Mouse Phenotypes related to Purpura:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.45 ACE ADAMTS13 CD40LG CD79A F2 F3
2 homeostasis/metabolism MP:0005376 10.43 ACE ADAMTS13 CD40LG CD79A CRP F2
3 immune system MP:0005387 10.43 ACE ADAMTS13 CD40LG CD79A CRP F2
4 cardiovascular system MP:0005385 10.38 ACE CD40LG CRP F2 F3 IL10
5 cellular MP:0005384 10.3 CD40LG CD79A F3 IL10 IL6 ITGA2B
6 mortality/aging MP:0010768 10.22 ACE ADAMTS13 CD40LG CD79A F2 F3
7 embryo MP:0005380 10.19 ACE F2 F3 IL10 ITGA2B ITGB3
8 digestive/alimentary MP:0005381 10.11 F2 IL10 IL6 ITGA2B ITGB3 THBD
9 liver/biliary system MP:0005370 10.07 ACE CD79A IL10 IL6 ITGB3 MEFV
10 integument MP:0010771 10.06 CD40LG F2 F3 IL10 IL6 ITGB3
11 nervous system MP:0003631 9.93 CD40LG CD79A F2 F3 IL10 IL6
12 neoplasm MP:0002006 9.8 ACE CD79A F3 IL10 IL6 ITGB3
13 reproductive system MP:0005389 9.7 ACE CD40LG F2 IL10 IL6 ITGA2B
14 respiratory system MP:0005388 9.23 F2 F3 IL10 IL6 ITGB3 PROC

Drugs & Therapeutics for Purpura

Drugs for Purpura (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 279)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
2
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
3
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
4
Hydroxychloroquine Approved Phase 4 118-42-3 3652
5
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
6
rituximab Approved Phase 4 174722-31-7 10201696
7
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
8
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
9
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
10 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
11
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
12
alemtuzumab Approved, Investigational Phase 4 216503-57-0
13
Morphine Approved, Investigational Phase 4 57-27-2 5288826
14
leucovorin Approved Phase 4 58-05-9 6006 143
15
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
16
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
17
Clarithromycin Approved Phase 4 81103-11-9 84029
18
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
19
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
20
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
21
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
22
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
23
Caffeic acid Experimental, Investigational Phase 4 331-39-5, 501-16-6 1549111
24
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
25
Enoxolone Investigational Phase 4 471-53-4 18526330
26 Antiparasitic Agents Phase 4
27 Antiprotozoal Agents Phase 4
28 Antimitotic Agents Phase 4
29 Antimalarials Phase 4
30 retinol Phase 4
31 Retinol palmitate Phase 4
32 Arnica Phase 4
33 Antibodies Phase 4
34 Immunoglobulins Phase 4
35 Immunologic Factors Phase 4
36 Antineoplastic Agents, Immunological Phase 4
37 Immunosuppressive Agents Phase 4
38 Dermatologic Agents Phase 4
39 Methylprednisolone Acetate Phase 4
40 Protective Agents Phase 4
41 Neuroprotective Agents Phase 4
42 Cyclosporins Phase 4
43 Antilymphocyte Serum Phase 4
44 Antimetabolites Phase 4
45 Folic Acid Antagonists Phase 4
46 Vitamin B Complex Phase 4
47 Vitamin B9 Phase 4
48 Folate Phase 4
49 Calcium, Dietary Phase 4
50 Cytochrome P-450 CYP3A Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 450)
# Name Status NCT ID Phase Drugs
1 A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP) Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
2 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
3 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
4 A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4 Eltrombopag olamine
5 A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
6 Off-label Use of Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis: Effectiveness and Safety Completed NCT03222687 Phase 4 tacrolimus;prednisone
7 The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia Completed NCT03258866 Phase 4 Rituximab;Rituximab
8 High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical Trial Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
9 An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen®) Who Have Shown Signs of Hemolysis Completed NCT01390649 Phase 4
10 Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag. Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
11 Multicenter, Randomized, Open, Parallel Controlled Trials Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP) Completed NCT04089267 Phase 4 TPO
12 HSP-glomerulonephritis Trial: MP vs CyA Completed NCT00425724 Phase 4 Methylprednisolone pulses plus prednisone versus Cyclosporine A
13 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
14 Randomized, Double-Blind, Contralateral, Controlled Study to Assess the Efficacy of DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Mature Skin of the Forearms and Hands Completed NCT01910831 Phase 4 DerMend Moisturizing Bruise Formula;Non-active placebo control
15 Influence of Plasma Exchange Therapy on the Pharmacokinetics of Rituximab in Patients Treated for Autoimmune Disorders. Completed NCT00820469 Phase 4 Rituximab 375;rituximab 1000
16 A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection Completed NCT01219764 Phase 4 Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
17 Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) Recruiting NCT03866798 Phase 4
18 Collection of Blood Samples From Patients With Relapsing Forms of Multiple Sclerosis (RMS) Who Have Developed Immune Thrombocytopenic Purpura (ITP) After LEMTRADA® Treatment Recruiting NCT03784898 Phase 4
19 A Single-center Prospective Randomized Study of Atorvastatin in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03692754 Phase 4 Atorvastatin 20mg;Atorvastatin 10mg
20 Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag Recruiting NCT01957176 Phase 4 ELT
21 A Single-center Prospective Randomized Study of Glycyrrhetinic Acid Combined With Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03998982 Phase 4 Glycyrrhetinic Acid;Dexamethasone
22 A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency) Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
23 Treatment With Thrombopoietin Mimetic Plus Immunosuppressive Therapy in Egyptian Patients With Aplastic Anaemia Recruiting NCT03896971 Phase 4 Combination of thrombopoietin mimetic and cyclosporin A
24 Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled Trial Recruiting NCT03771378 Phase 4 rhTPO;eltrombopag
25 Randomized Clinical Trial of the Use of Eltrombopag in Children With Idiopathic Aplastic Anemia Recruiting NCT03243656 Phase 4 Eltrombopag
26 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
27 Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia (ITP): A Multi-center Open Label Trial With Romiplostim Active, not recruiting NCT02760251 Phase 4 romiplostim
28 Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura Not yet recruiting NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
29 Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia in Pediatrics Not yet recruiting NCT04102033 Phase 4 Eltrombopag
30 A Multicenter Randomized Open-label Clinical Trial of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITP Not yet recruiting NCT04094805 Phase 4 Rocaltrol;Dexamethasone
31 Protocol for a Randomized, Placebo-Controlled, Double-Blinded Trial to Study the Effects of Supplementary Omega-3 Fatty Acids on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
32 Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura Withdrawn NCT01754545 Phase 4 Octaplas infusion and placebo (group 1);Octaplas infusion and placebo (group 2)
33 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP): a Prospective, Randomized Controlled Trial Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
34 AN OPEN-LABEL TRIAL OF REDUCED- DOSE PYLERA (BISMUTH, METRONIDAZOLE, TETRACYCLINE), AMOXICILLIN, AND ESOMEPRAZOLE IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION Withdrawn NCT02045251 Phase 4 Pylera based reduced regimen
35 Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn Withdrawn NCT03007381 Phase 4 Ketorolac Tromethamine;Normal Saline
36 Association of FC Gamma RIIIA Polymorphism and Thrombopoietin (THPO) Expression With Response to TPO Agonists in Refractory ITP and the Impact of Therapy on B and T Cells Subsets in the Patients With Mutated Genotypes Unknown status NCT02877212 Phase 3 Eltrombopag
37 A Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune Thrombocytopenia Unknown status NCT01805648 Phase 3 rhTPO
38 Thrombocytopenia in Gestational Period Unknown status NCT02751593 Phase 2, Phase 3 Dexamethasone
39 A Multicenter Randomized Study of Dexamethasone Combined With Rituximab, Cyclosporin and Intravenous Immunoglobulin in the Management of Newly Diagnosed ITP Patients Unknown status NCT02834468 Phase 3 DEX Combined With RTX, CSA and IVIG
40 A Multicenter Open-labeled Pilot Study on Recombinant Human Thrombopoietin in Management of Immune Thrombocytopenia in Pregnancy Unknown status NCT02391272 Phase 3 rhTPO
41 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP)in Pregnancy: a Single-center Clinical Trial Unknown status NCT02270801 Phase 3 rhTPO
42 Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
43 Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia Unknown status NCT02627417 Phase 3 Dapsone (Disulone®);Prednisone (Cortancyl®) alone followed by monitoring and "standard of care";Prednisone (Cortancyl®)
44 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura Completed NCT02076399 Phase 3 Fostamatinib disodium;Placebo
45 An Open Label Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT01071954 Phase 3
46 A Randomized, Double Blind, Placebo Controlled Phase 3 Study Evaluating the Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura Completed NCT00603642 Phase 3 Placebo;AMG 531
47 A Randomized, Open-label Study of First-line Treatment With Dexamethasone or Dexamethasone Plus MabThera on Sustained Treatment Response in Adult Patients With Idiopathic Thrombocytopenic Purpura Completed NCT00770562 Phase 3 rituximab;Dexamethasone
48 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura Completed NCT02076412 Phase 3 Fostamatinib Disodium;Placebo
49 Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)-An Extension Study of Eltrombopag in Subjects, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study TRA108109 (NCT00540423)-<Phase III Study> Completed NCT00828750 Phase 3 Eltrombopag oral tablets
50 An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT00508820 Phase 3

Search NIH Clinical Center for Purpura

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Epoprostenol
Epoprostenol Sodium

Cochrane evidence based reviews: purpura

Genetic Tests for Purpura

Anatomical Context for Purpura

MalaCards organs/tissues related to Purpura:

40
Skin, Bone, T Cells, Bone Marrow, Kidney, Spleen, Liver

Publications for Purpura

Articles related to Purpura:

(show top 50) (show all 22232)
# Title Authors PMID Year
1
Tissue deposits of IgA-binding streptococcal M proteins in IgA nephropathy and Henoch-Schonlein purpura. 54 61
20056836 2010
2
Henoch-Schönlein nephritis associated with streptococcal infection and persistent hypocomplementemia: a case report. 54 61
20181224 2010
3
[Henoch-Shönlein purpura]. 54 61
19345173 2009
4
Childhood Henoch-Schonlein nephritis: a multivariate analysis of clinical features and renal morphology at disease onset. 54 61
19377254 2009
5
Vasculitic IgA nephropathy: prognosis and outcome. 54 61
19342865 2009
6
Familial clusturing of Henoch-Schönlein purpura or IgA nephropathy: genetic background or environmental triggers? 54 61
19067882 2008
7
IgA nephropathy and Henoch-Schönlein purpura nephritis. 54 61
18332712 2008
8
The diagnostic value of IgA deposition in Henoch-Schönlein purpura. 54 61
18304186 2008
9
Splenic peliosis in the course of IgA nephropathy. 54 61
17885767 2007
10
Renal involvement in Henoch-Schönlein purpura: a multivariate analysis of initial prognostic factors. 54 61
17551657 2007
11
Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Schönlein-Henoch purpura nephritis. 54 61
17699418 2007
12
Thrombopoietin and interleukin-6 levels in Henoch-Schönlein purpura. 54 61
17164950 2006
13
Fatal relapse of thrombotic thrombocytopaenic purpura after cardiac surgery in patient with congenital absence of vWF-cleaving protease activity. 54 61
16421154 2006
14
Thrombotic thrombocytopaenic purpura in HIV-infected patients. 54 61
16105187 2005
15
[Effect of danshao granule on serum superoxide dismutase activity and malonyldialdehyde content in children with Henoch-Schonlein purpura nephritis]. 54 61
14714360 2003
16
A perspective on the measurement of ADAMTS13 in thrombotic thrombocytopaenic purpura. 54 61
12656756 2003
17
Immunoglobulin A-associated lymphocytic vasculopathy: a clinicopathologic study of eight patients. 54 61
12453297 2002
18
Acute glomerulonephritis. 54 61
10798062 1999
19
IgA nephropathy--human disease and animal model. 54 61
9154653 1997
20
Schönlein-Henoch purpura in adult patients. Predictive factors for IgA glomerulonephritis in a retrospective study of 57 cases. 54 61
9126006 1997
21
Hypergammaglobulinemic purpura associated with Sjögren's syndrome and chronic C type hepatitis. 54 61
9046734 1997
22
Inherited prethrombotic disorders and infectious purpura. 54 61
8822583 1996
23
Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. 54 61
8639762 1996
24
IgA-associated renal diseases. 54 61
8744534 1996
25
Serum anti-streptococcal IgA, IgG and IgM antibodies in IgA-associated diseases. 54 61
8503268 1993
26
Heavy and light chain composition of serum IgA and IgA rheumatoid factor in Henoch-Schönlein purpura. 54 61
1445457 1992
27
Protein C and S deficiency in severe infectious purpura of children: a collaborative study of 40 cases. 54 61
1430582 1992
28
Regional variation in C4 phenotype in patients with IgA nephropathy. 54 61
2329414 1990
29
[Schönlein-Henoch purpura and IgA nephropathy. A common pathogenetic cause?]. 54 61
2327670 1990
30
Correlation of urine protein/creatinine ratios to 24-h urinary protein for quantitating proteinuria in children. 61
31813022 2020
31
Accessory spleen embolization: An option for refractory idiopathic thrombocytopenic purpura (ITP). 61
31262671 2020
32
Fatal fulminant hemolysis-associated pulmonary embolism in mixed-type autoimmune hemolytic anemia: A case report. 61
32028408 2020
33
The leukotriene receptor antagonist Montelukast can induce adverse skin reactions in asthmatic patients. 61
31837440 2020
34
Transfusion-related acute lung injury (TRALI) after intravenous immunoglobulins: French multicentre study and literature review. 61
31760541 2020
35
Treatment of Refractory Henoch-Schonlein Purpura (HSP) with Dapsone: A Systematic Review. 61
32024340 2020
36
Update and Review of Bleeding Considerations in Dermatologic Surgery: Hemostatic Techniques and Treatment Strategies for Bleeding Complications. 61
31592926 2020
37
Rituximab-induced Henoch-Schonlein purpura in a patient with mantle cell lymphoma. 61
31408711 2020
38
Vasculitis with nonpalpable purpura resembling purpura fulminans. 61
31776714 2020
39
Henoch-Schönlein Purpura Nephritis and Cerebral Venous Sinus Thrombosis Due to Hereditary Deficiency of Antithrombin III. 61
31625017 2020
40
Thrombotic microangiopathy and liver toxicity due to a combination therapy of leflunomide and methotrexate: a case report. 61
32019572 2020
41
Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. 61
31691462 2020
42
IgA Vasculitis (Henoch-Schönlein Purpura) in Argentina: Comparison Between Pediatric and Adult Populations. 61
32029094 2020
43
In Reply, IgA Vasculitis (Henoch-Schönlein Purpura) in Argentina: Comparison Between Pediatric and Adult Population. 61
32029096 2020
44
Henoch-Schonlein purpura in pediatrics: Ten years of experience at a moderate risk office of a general hospital. 61
31984693 2020
45
Henoch-Schonlein Purpura Presenting With Bilateral Solid Testicular Masses in an Adult. 61
31722189 2020
46
Managing Preoperative Hemostasis in Patients with Inherited and Acquired Bleeding Disorders. 61
31887758 2020
47
Histological prognostic factors in children with Henoch-Schönlein purpura nephritis. 61
31696358 2020
48
Impact of CD40 gene polymorphisms on the risk of immune thrombocytopenic purpura. 61
32018016 2020
49
Predictive role of laboratory markers and clinical features for recurrent Henoch-Schönlein Purpura in childhood: A study from Turkey. 61
31711347 2020
50
The Epidemiology and Clinical Manifestations of Autoimmunity in Selective IgA Deficiency. 61
31267472 2020

Variations for Purpura

Expression for Purpura

Search GEO for disease gene expression data for Purpura.

Pathways for Purpura

Pathways related to Purpura according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.49 TNFSF13B TNF THPO MPL ITGB3 ITGA2B
2
Show member pathways
13.37 TNFSF13B TNF THPO ITGB3 ITGA2B IL6
3
Show member pathways
13.3 VWF TNFSF13B TNF ITGB3 ITGA2B IL6
4
Show member pathways
13.14 VWF THPO THBD SERPINC1 PROC MPL
5
Show member pathways
12.66 TNFSF13B TNF THPO IL6 CD40LG
6 12.47 TNFSF13B TNF MPL IL10 CD79A CD40LG
7
Show member pathways
12.3 THPO MPL IL6 IL10
8
Show member pathways
12.29 TNF IL6 F2 CRP
9
Show member pathways
12.19 THBD PROC ITGB3 F2
10
Show member pathways
12.18 TNF ITGB3 ITGA2B IL6 ACE
11 12.06 TNF THBD ITGB3 ITGA2B
12 11.97 VWF ITGB3 ITGA2B F2
13 11.95 TNF MEFV IL6 IL10
14
Show member pathways
11.94 VWF THBD SERPINC1 PROC F3 F2
15 11.85 TNF THBD IL6 F3
16 11.8 TNF THPO ITGB3 ITGA2B IL6
17 11.79 VWF THBD SERPINC1 PROC F3 F2
18 11.72 TNF IL6 IL10
19
Show member pathways
11.7 TNFSF13B TNF CD40LG
20 11.69 TNF THBD IL6 IL10
21 11.65 TNF ITGB3 IL6 IL10
22
Show member pathways
11.63 TNF IL6 CD40LG
23 11.62 ITGB3 IL10 CD40LG
24 11.49 TNF IL6 IL10
25 11.48 ITGB3 ITGA2B IL6
26 11.47 VWF ITGB3 ITGA2B F2
27 11.43 TNF IL6 IL10 CD40LG
28
Show member pathways
11.42 VWF THPO MPL ITGB3 ITGA2B F2
29 11.35 TNF IL6 IL10
30 11.3 TNF IL6 IL10
31 11.29 TNF THPO MPL ITGB3 ITGA2B IL6
32 11.2 TNF IL6 IL10
33 10.99 TNF IL6 CRP
34 10.83 TNFSF13B TNF THPO ITGB3 ITGA2B IL6

GO Terms for Purpura

Cellular components related to Purpura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 VWF TNFSF13B TNF THPO SERPINC1 PROC
2 cell surface GO:0009986 9.76 TNF THBD MPL ITGB3 ITGA2B F3
3 external side of plasma membrane GO:0009897 9.73 TNF ITGA2B F2 CD79A CD40LG ACE
4 endoplasmic reticulum lumen GO:0005788 9.72 SERPINC1 PROC IL6 F2 ADAMTS13
5 extracellular space GO:0005615 9.47 TNFSF13B TNF THPO THBD SERPINC1 PROC

Biological processes related to Purpura according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 9.94 VWF TNF ITGB3 ITGA2B
2 cellular protein metabolic process GO:0044267 9.93 SERPINC1 PROC IL6 F2
3 leukocyte migration GO:0050900 9.89 TNF THBD ITGB3 F2
4 positive regulation of protein phosphorylation GO:0001934 9.88 TNF THPO ITGB3 F2
5 cellular response to lipopolysaccharide GO:0071222 9.87 TNF IL6 IL10 ADAMTS13
6 cytokine-mediated signaling pathway GO:0019221 9.85 TNF MPL IL6 IL10 F3
7 inflammatory response GO:0006954 9.85 TNF MEFV IL6 IL10 CRP CD40LG
8 B cell differentiation GO:0030183 9.82 IL10 CD79A CD40LG
9 positive regulation of endothelial cell proliferation GO:0001938 9.8 ITGB3 IL10 F3
10 response to glucocorticoid GO:0051384 9.79 TNF IL6 IL10
11 positive regulation of T cell proliferation GO:0042102 9.76 TNFSF13B IL6 CD40LG
12 platelet activation GO:0030168 9.73 VWF ITGB3 IL6 F2 CD40LG ADAMTS13
13 integrin-mediated signaling pathway GO:0007229 9.71 ITGB3 ITGA2B CD40LG ADAMTS13
14 platelet aggregation GO:0070527 9.69 MPL ITGB3 ITGA2B
15 acute-phase response GO:0006953 9.67 IL6 F2 CRP
16 B cell proliferation GO:0042100 9.65 IL10 CD79A CD40LG
17 negative regulation of fibrinolysis GO:0051918 9.63 THBD F2
18 negative regulation of platelet activation GO:0010544 9.62 THBD F2
19 positive regulation of JAK-STAT cascade GO:0046427 9.62 TNF IL6 IL10 F2
20 endothelial cell apoptotic process GO:0072577 9.61 TNF IL10
21 neutrophil mediated immunity GO:0002446 9.6 IL6 ACE
22 negative regulation of cytokine secretion involved in immune response GO:0002740 9.56 TNF IL10
23 blood coagulation GO:0007596 9.56 VWF THBD SERPINC1 PROC ITGB3 F3
24 regulation of immunoglobulin secretion GO:0051023 9.55 TNF CD40LG
25 immunoglobulin secretion GO:0048305 9.54 TNFSF13B CD40LG
26 thrombopoietin-mediated signaling pathway GO:0038163 9.52 THPO MPL
27 negative regulation of lipid storage GO:0010888 9.46 TNF ITGB3 IL6 CRP
28 receptor biosynthetic process GO:0032800 9.43 TNF IL10
29 hemostasis GO:0007599 9.17 VWF THBD SERPINC1 PROC F3 F2

Molecular functions related to Purpura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.36 VWF TNFSF13B TNF THBD SERPINC1 PROC
2 identical protein binding GO:0042802 9.98 VWF TNF SERPINC1 MEFV ITGB3 ITGA2B
3 growth factor activity GO:0008083 9.67 THPO IL6 IL10 F2
4 integrin binding GO:0005178 9.56 VWF ITGB3 CD40LG ADAMTS13
5 protease binding GO:0002020 9.35 VWF TNF SERPINC1 ITGB3 F3
6 tumor necrosis factor receptor binding GO:0005164 9.33 TNFSF13B TNF CD40LG
7 fibrinogen binding GO:0070051 9.32 ITGB3 ITGA2B
8 cytokine activity GO:0005125 9.1 TNFSF13B TNF THPO IL6 IL10 CD40LG

Sources for Purpura

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....